简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
FDA
Medtide (03880.HK): Subsidiary Zhongtai Biochemical's Hangzhou Facility Successfully Passes FDA Pre-License Inspection, Paving Way for Commercial API Production of Hepcludex®
Tags:
MEDTIDE
03880.HK
FDA
2026-07-31
MICROPORT NEURO(02172.HK): NUMEN™ Helia Coil Obtains FDA Marketing Approval
Tags:
MICROPORT NEURO
02172.HK
FDA
2026-05-25
PEIJIA-B(09996.HK): First Patient Implant Completed in US Early Feasibility Study of GeminiOne® TEER System
Tags:
PEIJIA-B
09996.HK
FDA
2026-04-09
MICROPORT NEURO (02172.HK): APOLLO Dream® Stent System Granted FDA Breakthrough Device Designation – World’s First Neurointerventional Drug-Eluting Stent to Receive Such Designation
Tags:
MICROPORT NEURO
02172.HK
FDA
Breakthrough Device Designation
2026-03-18
Featured News
Research
HK shares Newly Listed Stocks Tracking Weekly Report: B&K CORP-B Leads with 68% Weekly Gain; INNOGEN-B Down Over 45% Cumulatively in Two Weeks Since Lock-up Expiry - 20260821
Research
HK Stock Connect Weekly Report: Hang Seng Index Rises 3.55% for the Week; Quarterly Review Results Unveiled, HUA HONG GRACE and ILUVATAR COREX Enter HSI and HSTECH - 20260821
Research
Going Global Weekly Report: Pharma Overseas Expansion Blossoms Across Fronts, A-Share Companies Accelerate Hong Kong Listings - 20260821
Research
HK Stock Connect Daily Report: MINIMAX-W Up Nearly 12%, Z.AI Up Over 10%, Southbound Net Sell of HKD 7.6 Billion - 20260821
Finance
Ingenic Semiconductor (03223.HK): H-Shares Offer Price Set at HK$100 Per Share
Finance
MOBVOI (02438.HK): Expects H1 Loss of RMB 45-58 Million
Finance
FAR INTL (02516.HK): Expects H1 Revenue Up 61%-110% and Turnaround or Narrower Loss
Finance
SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets
Finance
LEADS BIOLABS-B (09887.HK): NDA for Virexin as Treatment for Extrapulmonary Neuroendocrine Carcinoma Accepted by NMPA
Finance
SC HOLDINGS (00413.HK): Expects H1 Net Loss of HKD 400-500 Million
Scan QR Code
Download App